| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTSO | Common Stock | Exercise of in-the-money or at-the-money derivative security | $16.2K | +16.2K | +4.2% | $1.00 | 403K | Jan 17, 2025 | Direct | F1, F2, F3, F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTSO | Subscription Rights (right to buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -16.2K | -100% | $0.00 | 0 | Jan 17, 2025 | Common Stock | 16.2K | $1.00 | Direct | F1 |
| transaction | CTSO | Series A Right Warrants | Other | +16.2K | 16.2K | Jan 17, 2025 | Common Stock | 16.2K | Direct | F1, F6, F7 | ||||
| transaction | CTSO | Series B Right Warrants | Other | +16.2K | 16.2K | Jan 17, 2025 | Common Stock | 16.2K | Direct | F1, F8, F9 |
| Id | Content |
|---|---|
| F1 | On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 16,233 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $16,233. The Rights Offering closed on January 10, 2025 (the "Closing Date"). |
| F2 | Includes: (i) the following RSUs, which vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) that will settle into shares of common stock, par value $0.001 per share (the "Common Stock") upon vesting: 55,000 RSUs granted on July 7, 2023 and of which 18,334 RSUs remain unvested as of the date hereof; |
| F3 | (continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022; |
| F4 | (continued from footnote 3) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and remain unvested as of the date hereof; and |
| F5 | (continued from footnote 4) (iv) 148,691 shares of Common Stock owned by the reporting person. |
| F6 | The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00. |
| F7 | The Series A Right Warrants expire 45 calendar days following the Closing Date. |
| F8 | The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00. |
| F9 | The Series B Right Warrants expire 90 calendar days following the Closing Date. |